article thumbnail

AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B

Bio Pharma Dive

The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.

article thumbnail

Pfizer, BioNTech bet mRNA can make a better shingles vaccine

Bio Pharma Dive

The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi Cuts Jobs in U.S. Vaccines Division as Part of Restructuring

BioSpace

French healthcare and pharma company Sanofi will terminate an undisclosed number of positions in its U.S. vaccines commercial unit in an effort to streamline the strategic sales structure.

article thumbnail

mRNA Vaccine Manufacturing Comes to Africa

BioSpace

The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.

article thumbnail

Covid vaccine profits and the strain on supply channels

World of DTC Marketing

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. So far the winners are Pfizer and Moderna.

article thumbnail

COVID 19 vaccine means big money and greed

World of DTC Marketing

QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. Moderna, a 10-year-old vaccine developer based in Cambridge, Mass.,

article thumbnail

Pharma Companies Strike Deals to Deliver Millions of COVID-19 Vaccines by 2021

BioSpace

BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.